Literature DB >> 11057808

Cerebral blood flow and metabolism during and after prolonged hypercapnia in newborn lambs.

J K Hino1, B L Short, K Rais-Bahrami, W R Seale.   

Abstract

OBJECTIVE: To study the effects of prolonged (6 hrs) hypercapnia on cerebral blood flow and cerebral metabolism in newborn lambs and to evaluate the effects on cerebral blood flow and cerebral metabolism on return to normocapnia after prolonged hypercapnia.
DESIGN: Animal studies, using the newborn lamb, with comparison to control group.
SUBJECTS: Newborn lambs of mixed breed, 1-7 days of age, were used for the study. Two groups of animals were studied: a hypercapnic group (n = 10) and a normocapnic control group (n = 5).
SETTING: Work was conducted in the research laboratories at Children's National Medical Center, Washington, DC.
INTERVENTIONS: Animals were anesthetized with pentobarbital, intubated, paralyzed, and mechanically ventilated. After baseline measurements were made, CO2 was blended into the ventilator gas until a PaCO2 of 75-80 torr (10-10.6 kPa) was obtained. Measurements were made 1 hr after the desired PaCO2 was achieved and after 6 hrs of hypercapnia. After 6 hrs of hypercapnia, the ventilator gas was returned to the baseline value, that is, normocapnia. Measurements were made 30, 60, and 90 mins after PaCO2 returned to baseline. MEASUREMENTS: Six measurements were made during the study. For each measurement, blood samples were drawn from the sagittal sinus and brachiocephalic artery catheters and were analyzed for pH, hemoglobin concentration, oxygen saturation, and blood gas values. Cerebral blood flow (CBF) was measured by using the radiolabeled microsphere technique. Cerebral oxygen consumption, fractional oxygen extraction, and oxygen transport values were calculated at each study period. MAIN
RESULTS: Increasing PaCO2 from 37 +/- 3 torr to 78 +/- 6 torr (4.9 +/- 0.4 kPa to 10.3 +/- 0.8 kPa) for 1 hr increased CBF by 355%. After 6 hrs of PaCO2 at 78 +/- 3 torr (10.3 +/- 0.4 kPa), CBF remained 195% above baseline. At 30 mins of normocapnia, CBF had returned to baseline and remained at baseline until the conclusion of the study, a total of 90 mins of normocapnia. Cerebral oxygen consumption did not change during hypercapnia or with return to normocapnia. Oxygen transport increased 331% above baseline after 1 hr of hypercapnia and stayed 180% above baseline after 6 hrs of hypercapnia. Fractional oxygen extraction decreased by 55% at 1 hr of hypercapnia and stayed 39% below baseline at 6 hrs of hypercapnia.
CONCLUSIONS: Healthy lambs seem to tolerate undergoing hypercapnia for 6 hrs with a return to normocapnia. The return to baseline of CBF and cerebral metabolism at normocapnia seen in our study with lambs may explain why prolonged hypercapnia appears to be well tolerated in mechanically ventilated patients. If these results can be extrapolated to human subjects, our study in lambs supports evidence that patients who have undergone permissive hypercapnia seem to be neurologically unaffected.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11057808     DOI: 10.1097/00003246-200010000-00026

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  11 in total

1.  Alteration of the piglet diaphragm contractility in vivo and its recovery after acute hypercapnia.

Authors:  Samir Jaber; Boris Jung; Mustapha Sebbane; Michèle Ramonatxo; Xavier Capdevila; Jacques Mercier; Jean-Jacques Eledjam; Stefan Matecki
Journal:  Anesthesiology       Date:  2008-04       Impact factor: 7.892

Review 2.  Hypercapnic respiratory acidosis: a protective or harmful strategy for critically ill newborn foals?

Authors:  Modest Vengust
Journal:  Can J Vet Res       Date:  2012-10       Impact factor: 1.310

3.  Global cerebral oxidative metabolism during hypercapnia and hypocapnia in humans: implications for BOLD fMRI.

Authors:  J Jean Chen; G Bruce Pike
Journal:  J Cereb Blood Flow Metab       Date:  2010-04-07       Impact factor: 6.200

4.  A generalized procedure for calibrated MRI incorporating hyperoxia and hypercapnia.

Authors:  Claudine J Gauthier; Richard D Hoge
Journal:  Hum Brain Mapp       Date:  2012-01-16       Impact factor: 5.038

5.  ECMO for intractable status asthmaticus following atracurium.

Authors:  Vittorio Scaravilli; Giacomo Grasselli; Annalisa Benini; Michela Bombino; Daniele Ceriani; Uta Emmig; Alberto Zanella; Nicolò Patroniti; Antonio Pesenti
Journal:  J Artif Organs       Date:  2016-12-08       Impact factor: 1.731

Review 6.  Bench-to-bedside review: hypercapnic acidosis in lung injury--from 'permissive' to 'therapeutic'.

Authors:  Marloes M Ijland; Leo M Heunks; Johannes G van der Hoeven
Journal:  Crit Care       Date:  2010-11-03       Impact factor: 9.097

7.  Regional Reproducibility of BOLD Calibration Parameter M, OEF and Resting-State CMRO2 Measurements with QUO2 MRI.

Authors:  Isabelle Lajoie; Felipe B Tancredi; Richard D Hoge
Journal:  PLoS One       Date:  2016-09-20       Impact factor: 3.240

8.  Vascular autorescaling of fMRI (VasA fMRI) improves sensitivity of population studies: A pilot study.

Authors:  Samira M Kazan; Siawoosh Mohammadi; Martina F Callaghan; Guillaume Flandin; Laurentius Huber; Robert Leech; Aneurin Kennerley; Christian Windischberger; Nikolaus Weiskopf
Journal:  Neuroimage       Date:  2015-09-28       Impact factor: 6.556

9.  Application of calibrated fMRI in Alzheimer's disease.

Authors:  Isabelle Lajoie; Scott Nugent; Clément Debacker; Kenneth Dyson; Felipe B Tancredi; AmanPreet Badhwar; Sylvie Belleville; Yan Deschaintre; Pierre Bellec; Julien Doyon; Christian Bocti; Serge Gauthier; Douglas Arnold; Marie-Jeanne Kergoat; Howard Chertkow; Oury Monchi; Richard D Hoge
Journal:  Neuroimage Clin       Date:  2017-05-16       Impact factor: 4.881

10.  Does prolonged severe hypercapnia interfere with normal cerebrovascular function in piglets?

Authors:  Massroor Pourcyrous; Sandeep Chilakala; Mohamad T Elabiad; Helena Parfenova; Charles W Leffler
Journal:  Pediatr Res       Date:  2018-05-28       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.